| Autor: |
Li, Boyi, Sursal, Tolga, Martinez, Erick, Karimov, Zafar, Feldstein, Eric, Stein, Alan, Cooper, Jared, Hosein-Woodley, Rasheed, Liu, Aiden, McIntyre, Matthew, Bowers, Christian, Hanft, Simon, Hafeez, Zeeshan, Pisapia, Jared, Muh, Carrie, Tyagi, Rachana, Mayer, Stephan A., Gandhi, Chirag D., Al-Mufti, Fawaz |
| Předmět: |
|
| Zdroj: |
Interventional Neuroradiology; Aug2023, Vol. 29 Issue 4, p363-370, 8p |
| Abstrakt: |
Background: Heparin induced thrombocytopenia Type II (HIT-II) is a dangerous thromboembolic complication of heparin therapy. The current literature on incidence and outcomes of HIT-II in aneurysmal subarachnoid hemorrhage (aSAH) patients remains sparse. Objective: We report our institution's incidence and outcomes of HIT-II in aSAH patients. Methods: We performed a retrospective cohort study at an academic medical center between June 2014 and July 2018. All patients had aSAH confirmed by digital subtraction angiography. Diagnosis of HIT-II was determined by positive results on both heparin PF4-platelet antibody ELISA (anti-PF4) and serotonin release assay (SRA). Results: 204 patients met inclusion criteria. Seven patients (7/204, 3.5%) underwent laboratory testing, three of whom met clinical criteria. HIT-II incidence was confirmed in two of these seven patients (2/204, 0.98%), who had high BMI and T4 scores. Conclusion: Our institution's report of HIT-II incidence in aSAH patients is lower than previously reported in this population and more closely parallels HIT-II incidence in the general and surgical ICU setting. Widely-accepted American College of Chest Physicians (ACCP) clinical diagnostic criteria in conjunction with anti-PF4 and SRA testing is the gold standard of clinical diagnosis of HIT-II in aSAH patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
